Objectives: There is growing evidence that patients with community-onset pneumonia and recent healthcare exposure are not at equally high risk of infection with MDR organisms. An individualized approach is necessary with regard to risk assessment and choice of antibiotics.
Introduction
Pneumonia is the leading cause of infection-related hospitalizations and death and is also a major contributor to healthcare resource utilization in the USA. 1, 2 Following the publication of the 2005 healthcare-associated pneumonia (HCAP) guidelines, broadspectrum agent utilization nearly doubled. 3 In recent years, the rationale for MDR organism antibiotic coverage in HCAP has come into question and multiple new models have been developed to forecast the risk of MDR organisms in patients with pneumonia. Comparative evaluation of a select number of these models revealed that the drug resistance in pneumonia (DRIP) score at a cut-off 4 may have superior predictive performance in patients with community-onset pneumonia. 4 The aim of this study was to evaluate the effects of a stewardship-driven, DRIP score-based risk assessment programme on antibiotic utilization, all-cause readmissions and time to clinical improvement in patients presenting with community-onset pneumonia.
Methods

Study population
The institutional review board of Mount Sinai Health System granted approval for this study and waived the requirement of written informed consent. The cohort comprised patients admitted to our institution with community-onset pneumonia, who were identified retrospectively from hospital records by primary ICD codes. Patients were included in the study if they were identified to have a definite primary diagnosis of pneumonia and had the suspicion of drug-resistant infection by meeting any of the HCAP criteria from the guidelines. 
Intervention
In the usual care (UC) group, risk assessment for MDR organisms was mainly based on the 2005 guidelines. 5 Following the update of these in 2016, a revised risk assessment strategy using the DRIP score was developed to predict the risk of MDR organisms in the revised care (RC) group, in which a DRIP score 4 was considered to indicate a risk of MDR organisms, whereas a DRIP score ,4 was considered to indicate a low risk of MDR organisms. 4, 6 Data and outcomes of interest All data were collected retrospectively from the electronic medical records, which included the following: baseline demographics, laboratory information, clinical signs and symptoms of pneumonia, presence of sepsis, immunocompromised status, DRIP score, PORT score (pneumonia severity index), Charlson comorbidity index, history of prior hospitalizations, ICU length of stay, total hospital length of stay, mean antimicrobial days of therapy (DOT) utilization at the patient level, and history of previous exposure to antimicrobials. Time to clinical success was evaluated from day 3 to day 5 by two of the investigators (J. S. and C. S.). 7 When success could not be determined owing to lack of symptom information in the transcriptions or prolonged inpatient stay, the date of discharge or the date when the antibiotic course for pneumonia was finished was used. The primary outcome of interest was the estimated effect of implementing the DRIP scorebased algorithm on total days of broad-spectrum antimicrobial therapy. Secondary outcomes of interest were the effect of the intervention on 30 day all-cause readmissions and time to clinical improvement.
Statistical analysis
To evaluate for the imbalance between the characteristics of the two groups studied, the t statistic and the v 2 test were used. We calculated propensity scores to control for pre-intervention imbalances on observed variables before initiation of weighted regression modelling to obtain doubly robust estimates of the effects. 8 During regression modelling, nested model selection was based on Akaike information criterion (AIC) scores, forcing the intervention versus UC indicator to be included in all models. 9 Model fit was established and rated with Nagelkerke's R 2 and the HosmerLemeshow goodness-of-fit test, and based on the results of the Vuong test, and by visual examination of the rootograms. Intra-class correlation (ICC) Farkas et al.
estimates were calculated based on a mean-rating (k " 2), absoluteagreement, two-way random-effects model. HRs were calculated using Cox proportional hazards model regression. Non-parametric bootstrapping methods (n " 1000 samples) were applied to assess for the stability of the model parameter estimates. All statistical analyses were carried out using R V R software. 10 
Results
Demographic and clinical features of patients from the UC and RC groups are summarized in Table 1 . The full models of predictor variables for antibiotic utilization, readmissions and time to clinical improvement are presented in Table 2 , with the balance table available as Supplementary data at JAC Online (Table S1 ). The intervention resulted in a decrease in DOT for the anti-MRSA (#1.44, 95% CI #2.48 to #0.46) and anti-pseudomonal (#2.03, 95% CI #2.99 to #1.06) agents. Baseline Charlson comorbidity index (P , 0.05) was used in covariate adjustment in both models, with the addition of time to clinical improvement (P " 0.004) and the interaction between time to clinical improvement and a DRIP score 4 (P " 0.002) for the anti-pseudomonal agent utilization model. The presence of the intervention was not associated with a significant difference in the odds of readmissions between the two groups, with an OR of 0.64 (95% CI 0.16-2.57) favouring the intervention. Other dominant factors in the logistic model used for covariate adjustment include a DRIP score 4 (P , 0.001), immunosuppressed status (P " 0.153) and the PORT score (P " 0.048). Measures of ICC showed excellent agreement between the raters, with a value of 0.94 (95% CI 0.90-0.96). From the results of the Cox regression analysis, it was found that the intervention had no substantial effects on the hazard ratio of time to clinical improvement, with an HR of 1.19 (95% CI 0.62-2.21). Baseline serum lactate .2 mM (P " 0.006) and treatment with an agent that has activity against Pseudomonas aeruginosa (P " 0.005) were the significant covariates used in the adjustment process on time to clinical improvement.
Discussion
Our findings suggest that the change from the traditional HCAP criteria to an evaluation of risk based on the DRIP score was associated with a significant decrease in use of both the anti-pseudomonal and anti-MRSA antimicrobial agents. Implementation of this intervention did not result in an increase in the rates of future all-cause hospital readmissions in this patient population. Furthermore, the adjustment to this approach did not lead to any increase in time to clinical improvement.
In the RC group, we observed significantly shorter courses of anti-MRSA and anti-pseudomonal agent utilization. Studies evaluating the impact of stewardship-guided ordering guidelines for vancomycin also reported significant reduction in antibiotic use. [11] [12] [13] Anglim et al. 13 described a decrease of 50% in overall vancomycin use, while Shojania et al. 11 showed a somewhat more modest decline of 30% from baseline in the population of adults, outcomes that are very similar to those observed by Chiu et al. 12 in the neonatal age group. Other literature reports regularly account for an average decrease of 25%-60% in the overall utilization of targeted agents-including the anti-pseudomonals-when guidelines are utilized. 14, 15 Earlier studies evaluating the impact of adherence or implementation of pneumonia treatment guidelines also showed a positive impact on hospital readmissions. 16, 17 One study utilizing Medicare claims data found that pneumonia guideline implementation was associated with a lower 30 day readmission rate. 16 In our study, the presence of the intervention-based treatment was not associated with a significant difference in 30 day all-cause readmissions. Nevertheless, we realized a numerical trend towards lower rates of readmissions favouring the intervention. A limited number of indicators, like length of stay and indices of clinical cure, may be useful balancing measures, to help confirm that patients are not harmed through efforts to improve antimicrobial utilization. 18 A previous analysis of patients treated for community-onset pneumonia revealed that inappropriate treatment is mainly due to the presence of antibiotic-resistant pathogens, leading to longer hospital stays and higher rates of readmission. 19 After controlling for other plausible predictors in the Drug resistance in pneumonia JAC model, we identified no significant difference between the two groups in the expected hazard ratio for time to clinical improvement.
There are various considerations to bear in mind when interpreting the results of our study. This was a retrospective study with a small sample size, which alone may hinder the generalizability of the results. To mitigate some of the disadvantages associated with this design, we applied a propensity score-weighted approach to our analysis, selected objective and easily measurable results and applied bootstrapping to obtain better finite sample approximation of the estimators. Study data were limited to inpatient records; thus, endpoints reflect short-term data and may not fully represent the influence of post-discharge events on the selected outcomes. Also, as the approach to stewardship is rather systematic, involving strategies that are a combination of multiple interventions, it is possible that other factors we did not examine may have influenced our results. 20 To the best of our knowledge, no other stewardship strategy changed during the study period that could have significantly biased the results. Lastly, this analysis included patients from one urban academic hospital and it is unclear whether these outcomes apply to other regions or countries with different patient populations.
In conclusion, our study showed that the implementation of the DRIP score-based risk assessment of patients presenting with community-onset pneumonia was successful in reducing the use of broad-spectrum antibiotics. Such a reduction in broad-spectrum and high-risk antibiotics was achieved without an increase in adverse clinical outcomes.
